Posterior Distribution vs Tolerance intervals for Sampling Plan Determination in Pharmaceutical Manufacturing

Bayes2016, Leuven

20/05/2016

Martin Otava

Manufacturing, Toxicology and Applied Statistical Sciences EU Janssen Pharmaceutica, Belgium



Process development

- 1. Engineering runs: to make the process running
- 2. Characterization phase: to explore its basic properties
- 3. Factors optimization: designed experiments, optimization
- 4. Validation phase: to evaluate the final process setup
- 5. Production phase: to be able to detect any possible issues occurring in the process

Process performance qualification (PPQ) protocol

- Protocol of final validation experiment
- Data available from previous stages (engineering runs, characterization study, DoE)
- Different settings for different data sources



Example Data Set (simulated):

- 12 Batches from pre-PPQ studies of varying purpose
- 4 Batches: 8 Bags, 5 observations per bag
- 8 Batches: 8 Bags, only 1 observation per Bag
- Simulated data set based on structure of real data set (but all the value of parameters are completely artificial)
- Response: % of label claim
- Acceptance criteria: each individual value between 90-110
- Future experiment: 3 Batches, 10 Bags, 1 Sample

Janssen $\overline{\mathcal{F}}$ | pharmaceutical c

Data set



janssen 🗍

PPQ protocol

- Main question:
- Sampling plan for validation experiment
- Our focus:
- Asses the quality of the process
- Estimate probability of passing validation experiment (given the sampling plan)



Methodology

Frequentist framework

- $Y = N(\mu, \sigma^2)$
- Point estimate of μ
- 95% **Confidence interval** on μ : confidence statement on parameter estimate
- 99% **Prediction interval** for *Y*: interval containing future observation with confidence of 99%
- 99%/95% **Tolerance interval** for *Y*: interval containing 99% future observations with confidence of 95%



99%/95% Tolerance interval

- One-sided: confidence statement about 99% quantile
- Two-side: more complex problem
- Typically centred around the mean
- Normal case approximately (one of many formulas):

$$\hat{\mu} \pm \sqrt{\frac{\nu\left(1 + \frac{1}{N}\right)z^2_{(1-p)/2}}{\chi^2_{1-\alpha,\nu}}}\sqrt{\widehat{\sigma^2}}$$

janssen 🎵

pharmaceutical companie: of Johnson-Johnson

Bayesian framework

- $Y = N(\mu, \sigma^2)$
- Posterior distribution of parameters available
- Sampling from posterior can be done (within fitting the chain)
- Samples of individual values can be obtained
- Simulation of future experiment can be done



Posterior probabilities of "success"

- 1. At each iteration of MCMC simulate future experiment
- 2. Apply acceptance criteria on the simulated experiment (simple threshold or complex decision tree)
- 3. Record indicator of passing/failing the criteria
- 4. Mean of indicator = Posterior probability of passing the test for future experiment
- Assumption: future process will behave similarly to current one
- Typically conservative solution



pharmaceutical companie: df Johnnon«Johnnon

"Bayesian" 99%/95% tolerance intervals

- 1. At each iteration, sample parameters μ, σ^2
- 2. Compute quantiles of respective normal distribution
- 3. Obtain posterior distribution of quantiles
- 4. Estimation 99%/95% tolerance interval
- Wolfinger vs Krishnamoorthy & Mathew: how to determine two-sided tolerance interval?



Comparison: W vs K&M

Small subset



Points in these areas causes difference between methods.



Alternative Bayesian tolerance intervals

- Sampling from the posterior distribution of individual values
- 99% content Tolerance interval: 99% credible interval on individual values
- Related to 99% prediction interval
- Interpretation of uncertainty in terms of posterior distribution



Application

Data set



janssen 🗍

Model

• The following linear mixed model was fitted to the data of all batches:

$$y_{ijk} = \mu_0 + b_i + c_{ij} + \varepsilon_{ijk}$$

where

- y_{ijk} = response for the *k*-th value of *j*-th bag in the *i*-th batch
- μ_0 = the process mean
- b_i = random effect of *i*-th batch: $b_i \sim N(0, \sigma_b^2)$
- c_{ij} = random effect of *j*-th bag of *i*-th batch: $c_{ij} \sim N(0, \sigma_c^2)$
- $\varepsilon_{ijk} = \text{residual error: } \varepsilon_{ijk} \sim N(0, \sigma_{\varepsilon}^2).$

Note on priors

- Typically "non-informative" type of priors
- Sometimes experiments from previous stages (DoE) are used
- Their relevance is questionable
- Their questionable relevance corresponds to the reason why they are not included in the data set to be analysed

Output

Estimates	Mean	2.5% CI*	97.5% CI	Truth
Process mean	99.82	99.48	100.16	100.00

Source of variability	Median	2.5% CI	97.5% CI	Truth
Batch	0.55	0.36	0.92	0.50
Bag	0.31	0.24	0.38	0.30
Residual	0.25	0.22	0.28	0.25

*CI here stand for Credible Interval

janssen 🕇

PHARMACEUTICAL COMPANIES OF Johnson Johnson

Output: tolerance intervals

Tolerance intervals	Lower	Upper
99%/95% Wolfinger	97.60	102.05
99%/95% K & M	97.20	102.44
99% content Tolerance interval	97.82	101.84
True quantiles (0.5%, 99.5%)	98.37	101.63

- We do expect that TIs will be wider than true quantiles
- We do expect that 99%/95% TIs will be wider than 99% content
- We do expect to see difference between W and K&M



Output: Posterior probability

Posterior probability	
Passing acceptance criteria	1*

*Not really 1

- Typical result in practical applications in late stage of development
- Real meaning: "it has never happened in my simulated MCMC that..."
- Depends on number of chains, iteration, thinning & correlation
- In this example (worst case scenario) >99.91%



Conclusions

Summary

- Posterior probability and TIs connected, but approaching main question from different viewpoints
- Reporting both of them has added value
- Bayesian approach allows us to:
 - estimate both quantities directly
 - fit more complex models without much extra effort
 - use of prior information
 - BUT, be careful with: 99%/95% TIs computation specification of priors computational time

Janssen J Pharmaceutical companies of Johnnon-Johnnon

References

- Wolfinger, R. D. (1998): Tolerance intervals for variance component models using Bayesian simulation. *Journal of Quality technology*, 30(1)
- Krishnamoorthy, K. & Mathew, T. (2009): Statistical Tolerance Regions: Theory, Applications, and Computation. ISBN: 978-0-470-38026-0





motava@its.jnj.com

20/05/2016



Janssen

PHARMACEUTICAL COMPANIES OF Johnson Johnson